Sarepta Therapeutics

Marissa Penrod and Kelly Maynard sought to help families facing challenges beyond Duchenne after their sons, Joseph and Jackson, were diagnosed at age five; Joseph was diagnosed in 2008 and Jackson four years later.

Sarepta recently joined forces with leading rare disease organizations—including the EveryLife Foundation for Rare Diseases, Orchard Therapeutics, BioMarin Pharmaceutical, and Retrophin—to

A behind-the-scene look at photographer Glynis Carpenter and the resulting photograph

Sarepta is developing precision genetic medicines for patients with rare diseases, including Duchenne, who often have limited or no treatment options. Clinical trials are critical to understanding the safety and effectiveness of investigational medicines.

Sarepta seeks people with a commitment to patients.

The page presents Sarepta's leadership and their goal to change the course of genetic disease.

Sarepta aims to change the course of genetic disease and is committed to developing precision genetic medicines for rare genetic conditions.

Sarepta, a global biopharmaceutical company, has locations throughout the world. View a list of global locations.

The company provides grants, donations, medical education support, and sponsorships to advocacy groups, nonprofit organizations, academic institutions, and scientific and medical associations.

Sarepta is committed to supporting patients throughout their journey, with partnerships with patient advocacy groups as a fundamental part of this work.

Sarepta can be contacted by phone or email.

Sarepta focuses on developing precision genetic medicines to treat rare neuromuscular and central nervous system diseases.

The company has a privacy policy for its website.